Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma

European Respiratory Journal

Volumn 33, Issue 6, 2009, Pages 1277-1286

  Derom, E ^a   Louis, R ^b   Tiesler, C ^c   Engelstatter R ^c   Kaufman, J M ^a   Joos, G F ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c ALTANA Pharma Nycomed   (Germany)

Author keywords

Aerosol therapy; Anti asthmatic agent; Asthma; Bronchial hyperreactivity; Cortisol; Inhaled corticosteroids

Indexed keywords

ADENOSINE; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; CICLESONIDE; FLUTICASONE; FORMOTEROL; HYDROCORTISONE; METHACHOLINE; PLACEBO; SALMETEROL;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; HORMONE INHIBITION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; LOW DRUG DOSE; MALE; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADENOSINE; ADOLESCENT; ADULT; AGED; ALBUTEROL; ANALYSIS OF VARIANCE; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; AREA UNDER CURVE; ASTHMA; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTOR AGENTS; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYDROCORTISONE; LEAST-SQUARES ANALYSIS; MALE; METHACHOLINE CHLORIDE; MIDDLE AGED; PLACEBOS; PREGNENEDIONES; SPIROMETRY; TREATMENT OUTCOME;

EID: 69249151708     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00079908     Document Type: Article

References (47)

1. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157: S1-S53.
2. Banov C, Howland WC III, Lumry WR, et al. Budesonide turbuhaler delivered once daily improves health-related quality of life in adult patients with non-steroid-dependent asthma. Allergy Asthma Proc 2003; 24: 129-136.
3. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002; 57: 880-884.
4. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332-336.
5. Global Initiative for Asthma (GINA) Executive Committee. Global Strategy for Asthma Management and Prevention. GINA 2006. www.ginasthma.com Date last accessed: April 3, 2009. Date last updated: December 2008.
6. Kelly HW. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol 2003; 112: 469-478.
7. Todd GR, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87: 457-461.
8. Bender BG, Bender SE. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin North Am 2005; 25: 107-130.
9. Adams RJ, Fuhlbrigge A, Guilbert T, et al. Inadequate use of asthma medication in the United States: results of the asthma in America national population survey. J Allergy Clin Immunol 2002; 110: 58-64.
10. Mutch E, Nave R, McCracken N, et al. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol 2007; 73: 1657-1664.
11. Pearlman DS, Berger WE, Kerwin E, et al. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol 2005; 116: 1206-1212.
12. Wilson AM, Duong M, Pratt B, et al. Anti-inflammatory effects of once daily low dose inhaled ciclesonide in mild to moderate asthmatic patients. Allergy 2006; 61: 537-542.
13. Langdon CG, Adler M, Mehra S, et al. Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med 2005; 99: 1275-1285.
14. Derom E, Van De Velde V, Marissens S, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005; 18: 328-336.
15. Lee DK, Fardon TC, Bates CE, et al. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest 2005; 127: 851-860.
16. Lipworth BJ, Kaliner MA, La Force CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 2005; 94: 465-472.
17. Szefler S, Rohatagi S, Williams J, et al. Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 2005; 128: 1104-1114.
18. Weinbrenner A, Huneke D, Zschiesche M, et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 2002; 87: 2160-2163.
19. Lönnebo A, Grahnén A, Jansson B, et al. An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Eur J Clin Pharmacol 1996; 49: 459-463.
20. Derom E, Van Schoor J, Verhaeghe W, et al. Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma. Am J Respir Crit Care Med 1999; 160: 157-161.
21. Clark DJ, Lipworth BJ. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax 1997; 52: 55-58.
22. Edsbäcker S, Wollmer P, Selroos O, et al. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids? Pulm Pharmacol Ther 2007; 21: 247-258.
23. Lee DK, Haggart K, Currie GP, et al. Effects of hydrofluoroalkane formulations of ciclesonide 400 microg once daily vs fluticasone 250 microg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. Br J Clin Pharmacol 2004; 58: 26-33.
24. Thorsson L, Dahlstrom K, Edsbäcker S, et al. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1997; 43: 155-161.
25. Cockcroft DW, Killian DN, Mellon JJ, et al. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977; 7: 235-243.
26. Gallo PP. Center-weighting issues in multicenter clinical trials. J Biopharm Stat 2000; 10: 145-163.
27. Whelan GJ, Blumer JL, Martin RJ, et al. Fluticasone propionate plasma concentration and systemic effect: effect of delivery device and duration of administration. J Allergy Clin Immunol 2005; 116: 525-530.
28. Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356: 556-561.
29. Harrison TW, Tattersfield AE. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 2003; 58: 258-260.
30. Weiner P, Berar-Yanay N, Davidovich A, et al. Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest 1999; 116: 931-934.
31. Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006; 28: 1042-1050.
32. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide. J Clin Pharmacol 2007; 47: 782-789.
33. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836-844.
34. Prosperini G, Rajakulasingam K, Cacciola RR, et al. Changes in sputum counts and airway hyperresponsiveness after budesonide: monitoring anti-inflammatory response on the basis of surrogate markers of airway inflammation. J Allergy Clin Immunol 2002; 110: 855-861.
35. Medici TC, Grebski E, Hacki M, et al. Effect of one year treatment with inhaled fluticasone propionate or beclomethasone dipropionate on bone density and bone metabolism: a randomised parallel group study in adult asthmatic subjects. Thorax 2000; 55: 375-382.
36. Li JT, Ford LB, Chervinsky P, et al. Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. J Allergy Clin Immunol 1999; 103: 1062-1068.
37. Kraan J, Koëter GH, van der Mark TW, et al. Dosage and time effects of inhaled budesonide on bronchial hyperreactivity. Am Rev Respir Dis 1988; 137: 44-48.
38. Taylor DA, Jensen MW, Kanabar V, et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 237-243.
39. Nielsen LP, Dahl R. Therapeutic ratio of inhaled corticosteroids in adult asthma. A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function. Am J Respir Crit Care Med 2000; 162: 2053-2057.
40. Ward C, Pais M, Bish R, et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002; 57: 309-316.
41. Peachell PT, Columbo M, Kagey-Sobotka A, et al. Adenosine potentiates mediator release from human lung mast cells. Am Rev Respir Dis 1988; 138: 1143-1151.
42. Polosa R, Li Gotti F, Mangano G, et al. Monitoring of seasonal variability in bronchial hyper-responsiveness and sputum cell counts in non-asthmatic subjects with rhinitis and effect of specific immunotherapy. Clin Exp Allergy 2003; 33: 873-881.
43. van den Berge M, Kerstjens HA, Meijer RJ, et al. Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med 2001; 164: 1127-1132.
44. Joos GF, O'Connor B, Anderson SD, et al. Indirect airway challenges. Eur Respir J 2003; 21: 1050-1068.
45. Phillips K, Oborne J, Lewis S, et al. Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide. Thorax 2004; 59: 26-30.
46. Kanniess F, Richter K, Böhme S, et al. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther 2001; 14: 141-147.
47. Currie GP, Fowler SJ, Lipworth BJ. Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis. Ann Allergy Asthma Immunol 2003; 90: 194-198.